Potensi Tepezza (Teprotumumab) dalam Pengobatan Penyakit Mata Tiroid Aktif (TED)

Dewi Samudra Putri Aliffa Rukmana; Rani Nurmala Ramzi; Jevon Dhuarte; Fitra Jaya; Santi  Anugrahsari

doi:10.36452/JMedScientiae.v3i2.3010

Authors

Dewi Samudra Putri Aliffa Rukmana Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
Rani Nurmala Ramzi Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
Jevon Dhuarte Fakultas Kedokteran dan Ilmu Kesehatan Universitas Kristen Krida Wacana, Jakarta, Indonesia
Fitra Jaya Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
Santi Anugrahsari Departemen Mata, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia. https://orcid.org/0000-0001-6712-6968

DOI:

https://doi.org/10.36452/JMedScientiae.v3i2.3010

Keywords:

Active Thyroid Eye Disease (TED), Tepezza, Teprotumumab, IGF-1R, TED treatment

Abstract

Abstract

Active Thyroid Eye Disease (TED) is a medical condition involving swelling of the muscles, tissues, and fats around the eyes. This can lead to serious symptoms including double vision and vision loss. Tepezza (Teprotumumab) is an innovative therapy that inhibits the insulin-like growth factor 1 receptor (IGF-1R) and has been approved for TED treatment. Teprotumumab works by reducing inflammation and TED symptoms. Pharmacokinetic studies indicate that this drug can be effectively administered via intravenous infusion. Various studies have shown that teprotumumab can significantly reduce proptosis, diplopia, and clinical activity of TED. This therapy has proven effective in various patient groups, including those with long-standing TED and those unresponsive to other treatments. Teprotumumab holds a promising breakthrough in TED management, improving the quality of life for individuals affected by this disease. Further studies are needed to fully understand the mechanism and potential of teprotumumab in TED treatment.